These are independent reviews of the products mentioned, but TIME receives a commission when purchases are made through affiliate links at no additional cost to the purchaser.
Lecanemab (Leqembi), made by Eisai and Biogen, is only the second drug approved by the FDA to treat Alzheimer’s disease, and it may be the most effective. In studies, Leqembi slowed cognitive decline as measured on tests and tasks of daily living by 27% compared to placebo. Patients receive the drug, which helps to reduce build up of the amyloid protein in the brain that can compromise brain function, intravenously once every two weeks at an infusion center. The drug can cause brain swelling, especially among those with genes that put them at higher risk for developing Alzheimer’s, but regular scans and tapering back on doses can control that risk.
More Must-Reads from TIME
- How Kamala Harris Knocked Donald Trump Off Course
- Inside the Rise of Bitcoin-Powered Pools and Bathhouses
- What Makes a Friendship Last Forever?
- 33 True Crime Documentaries That Shaped the Genre
- Long COVID Looks Different in Kids
- Your Questions About Early Voting, Answered
- Column: Your Cynicism Isn’t Helping Anybody
- The 100 Most Influential People in AI 2024
